A Novel NF‐κB Inhibitor, Edasalonexent (CAT‐1004), in Development as a Disease‐Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects

In Duchenne muscular dystrophy (DMD), NF‐κB is activated in skeletal muscle from infancy regardless of the underlying dystrophin mutation and drives inflammation and muscle degeneration while inhibiting muscle regeneration. Edasalonexent (CAT‐1004) is a bifunctional orally administered small molecul...

Descripción completa

Detalles Bibliográficos
Autores principales: Donovan, Joanne M., Zimmer, Michael, Offman, Elliot, Grant, Toni, Jirousek, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Pharmacokinetics/Pharmacodynamics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412838/
https://www.ncbi.nlm.nih.gov/pubmed/28074489
http://dx.doi.org/10.1002/jcph.842

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412838/
https://www.ncbi.nlm.nih.gov/pubmed/28074489
http://dx.doi.org/10.1002/jcph.842

Ejemplares similares